Skip to main content

Adenoviral Vectors for Gene Therapy

  • 3rd Edition - April 9, 2025
  • Latest edition
  • Editors: David T. Curiel, Alan L. Parker
  • Language: English

Adenoviral Vectors for Gene Therapy, Third Edition, provides detailed, comprehensive coverage of gene delivery vehicles based on the adenovirus that is emerging as an important… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Description

Adenoviral Vectors for Gene Therapy, Third Edition, provides detailed, comprehensive coverage of gene delivery vehicles based on the adenovirus that is emerging as an important tool in gene therapy. These exciting new therapeutic agents have great potential for the treatment of disease, as platforms for gene therapy and gene editing, as well as for oncology approaches, making them class leading agents in the gene-advanced therapies arena.

The fully updated and expanded third edition covers the basic biology of adenoviruses and highlights the potential use of adenoviral vectors for the treatment of disease, including their construction, propagation, and purification, cutting-edge vectorology, and the use of adenoviral vectors in preclinical animal models. The book also considers the regulatory issues surrounding human clinical gene therapy trials. New chapters include adenoviral vaccines for veterinary applications, adenoviruses for gene editing, nonhuman primate adenoviruses, COVID-19 vaccines, vaccine applications, and oncolytic adenoviruses for antitumor immunization. This broad scope of information provides a solid overview of the field, allowing the reader to gain a complete understanding of the development and use of adenoviral vectors.

Key features

  • Provides complete coverage of the basic biology of adenoviruses, as well as their construction, propagation, and purification of adenoviral vectors
  • Introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement
  • Demonstrates noninvasive imaging of adenovirus-mediated gene transfer
  • Discusses the utility of adenoviral vectors in animal disease models
  • Considers Food and Drug Administration regulations for human clinical trials

Readership

Researchers in virology, genetics (specifically gene therapy) and others engaged in therapeutics research; "translational" physician-scientists will find this a unique resource for understanding the clinical issues of applying adenoviral vectors

Table of contents

1. Structural Biology of Adenovirus

2. Biology of Adenovirus Cell Entry: Receptors, Pathways, Mechanisms

3. Adenovirus Replication

4. Adenoviral Vector Construction I: Mammalian Systems

5. Adenoviral Vector Construction II: Bacterial Systems

6. Adenoviral Vector Packing Cell Lines

7. Purification of Adenovirus

8. Innate Immune Response to Adenovirus

9. Antibodies to Adenovirus

10. Methods to Mitigate Immune Response

11. Xenogenic Adenoviral Vectors as Vaccines

12. Adenoviral Vector Targeting

13. Helper-Dependent Adenovirus

14. Hybrid Adenoviral Vectors

15. Canine Adenovirus

16. Oncolytic Adenovirus

17. Imaging Analysis

18. Adenoviral Vaccines - Cancer

19. Adenoviral Vaccines - Infectious Disease

20. Adenoviral Vaccines - COVID 19

21. Adenoviral Vectored Veterinary Vaccines

22. Utility of Adenoviral Vectors in Animal Models - CV Disease

23. Utility of Adenoviral Vectors in Animal Models - Pulmonary Disease

24. Utility of Adenoviral Vectors in Animal Models - Genetic Disease

25. Adenoviral Vectors for Gene Editing

26. Manufacturing and Upscaling

27. Regulation of Adenoviral Vector-Based Therapies: An FDA Perspective

Product details

  • Edition: 3
  • Latest edition
  • Published: June 12, 2025
  • Language: English

About the editors

DC

David T. Curiel

David T. Curiel, M.D., Ph.D. is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. Dr. Curiel graduated medical school at Emory University in 1982, where he also completed his internship and residency in Internal Medicine. Dr. Curiel’s scientific training includes tenureship at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI) from 1985-1989, and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch from 1989-1990. He received his Ph.D. from University of Groningen in The Netherlands in 2002. Dr. Curiel has been at Washington University School of Medicine since 2011. In addition to his role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.
Affiliations and expertise
Washington University School of Medicine, St. Louis, MO, USA

AP

Alan L. Parker

Affiliations and expertise
Professor of Translational Virotherapies, Head of Section of Solid Cancers, Division of Cancer and Genetics, University of Cardiff, UK

View book on ScienceDirect

Read Adenoviral Vectors for Gene Therapy on ScienceDirect